. Author manuscript; available in PMC: 2016 Mar 14.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2014 May 24;89(4):830–838. doi: 10.1016/j.ijrobp.2014.03.034

Table 4.

Tissue biomarker expression and distribution after neoadjuvant proton therapy and chemotherapy in PDACs

Biomarker	Intratumoral	Stromal	P value
SDF1α (CXCL12) score (n=32)	2.5 ± 1.0 (32)	1.8 ± 0.6 (31)	.0001
CXCR4 (cytoplasmic) score	3.0 ± 1.0 (32)	3.5 ± 0.8 (31)	.0067
CXCR4 (membranous) score	1.6 ± 0.7 (32)	3.5 ± 0.8 (31)	<.0001
CXCR7 score	3.1 ± 1.0 (32)	2.3 ± 0.6 (31)	.0004
CD31 + vessel density	8.7 ± 6.6 (32)	9.2 ± 6.5 (31)	.45
CD31+/α-SMA + vessel density	7.5 ± 5.6 (32)	8.5 ± 4.5 (31)	.21
CD68+ macrophage (area fraction)	0.056 (0.040–0.081) (32)	0.037 (0.029–0.051) (32)	.0029
Fibrosis score	2.3 ± 0.7 (32)		NA

Abbreviations: NA = not applicable; PDAC = pancreatic ductal adenocarcinoma.

Data are shown as hazard ratios with 95% confidence intervals.

P values are from a Wald test in a univariable Cox regression.